Prescription Digital Therapeutics for Mental Health: What FDA Clearance Does and Does Not Mean

In April 2024, the U.S. Food and Drug Administration cleared Rejoyn, the first prescription digital therapeutic for major depressive disorder, and the single word "cleared" carries most of the meaning. Rejoyn is authorized only as an adjunct to antidepressant medication and clinician-managed outpatient care for adults 22 and older, not as a standalone treatment and not as a cure. It reached the market through the 510(k) clearance pathway, which rests on substantial equivalence to an existing device rather than the independent demonstration of safety and effectiveness that a full approval requires. And in its pivotal trial, the pre-specified primary endpoint did not meet the conventional threshold for statistical significance.

Cleared is not the same as approved

The FDA uses these words with precision, and the difference is legal, not cosmetic. The agency "clears" many devices through the 510(k) pathway by finding them substantially equivalent to a product already on the market, called a predicate. It "approves" higher-risk devices through premarket approval only after an independent showing of safety and effectiveness, and it "approves" drugs through a separate new-drug or biologics process. Rejoyn was cleared, not approved. Its clearance rests on a predicate device that was already marketed, and substantial equivalence asks whether the new product shares that predicate's intended use and is as safe and effective as it is. That question is narrower than the one a drug approval answers. Describing a cleared device as "FDA approved" misstates its regulatory category, and for medical devices that is an enforceable distinction rather than a semantic quibble.

What the pivotal trial actually measured

The clearance rested on the Mirai study, a 13-week, remote, double-blind randomized controlled trial later published in the Journal of Affective Disorders. It enrolled 386 adults aged 22 to 64 who had major depressive disorder and were already taking antidepressants, then randomized them to Rejoyn or to a sham app designed to look and feel similar. The active program ran six weeks, followed by a four-week extension for follow-up. The primary endpoint was the change in the Montgomery-Asberg Depression Rating Scale, or MADRS, from baseline to week six.

Here is the part that rarely survives into a headline. In the primary analysis, MADRS scores fell 9.03 points in the Rejoyn group and 7.25 points in the sham group. The difference was 1.78 points, with a p-value of 0.0568. By the usual 0.05 convention, that primary comparison did not reach statistical significance. A supportive analysis of the full randomized sample produced a difference of 2.12 points and a p-value of 0.0211, which did cross the threshold. Both numbers appear in the peer-reviewed report, and an honest reading holds both in view.

Why the sham group changes the story

Look at what happened in the control arm. People using the sham app improved by more than seven MADRS points, a large move on its own. That improvement reflects the antidepressant they were already taking, the clinician care around them, the natural waxing and waning of depressive episodes, and the simple act of engaging with a daily app while expecting to feel better. A well-built digital sham controls for most of that. What remains, the effect attributable to Rejoyn's specific exercises, was on the order of two MADRS points. That is a modest signal, and it explains why the primary endpoint sat on the edge of significance. On safety the picture was cleaner: the trial reported no adverse events attributed to the app, which is a genuine advantage of the category.

"Adjunct" is a load-bearing word

The authorized indication is adjunctive, layered on top of ongoing antidepressant treatment and clinician care in adults 22 and older. The manufacturer states plainly that Rejoyn is not intended as a standalone therapy or a substitute for medication. So the trial answered a specific question: does adding this app to existing drug treatment help somewhat? It did not test whether the app can replace medication, replace psychotherapy, or work in people who are not already under a clinician's care. Marketing phrases such as "clinically validated" and "first authorized" are accurate and also easy to over-read. They describe a regulatory milestone and a directional benefit, not a cure and not a reason to change or stop a prescription.

How to read a digital therapeutic's claim

A few questions separate signal from packaging. Was the product cleared or approved, and through which pathway? Is it authorized as a standalone treatment or only as an adjunct, and for which population? Did the trial's pre-specified primary endpoint succeed, or does the strongest number come from a secondary or supportive analysis? What was the comparator, an active or sham control that mimics the experience, or a waitlist that does not? And is the effect clinically meaningful, or merely statistically detectable in a large sample? Durability matters too, since a benefit at six weeks says little about six months.

None of this makes prescription digital therapeutics unimportant. A safe, scalable tool that adds a couple of points of symptom relief on top of standard care can matter, especially where access to psychotherapy is thin. The task is to match expectations to evidence. This article is educational and not medical advice, and decisions about depression treatment belong with a qualified clinician who knows the individual.